查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573666

癌症切片市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cancer Biopsy Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 205 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球癌症活體組織切片市場價值為215 億美元，預計2024 年至2032 年複合年成長率為8.4%。 。

液體活體組織切片和次世代定序 (NGS) 等技術因其精確性和微創方法而受到關注。這些進步正在徹底改變癌症診斷，為疾病檢測和監測提供侵入性較小、更準確的方法。美國國家癌症研究所 (NCI) 2019 年的一份報告強調，液體活體組織切片可以檢測超過 70% 的晚期癌症病例的基因突變，旨在加強早期檢測、制定治療策略並改善患者預後。

人們對遺傳性腫瘤疾病和基因檢測重要性的認知不斷提高，需求不斷擴大。這些技術有助於早期檢測和個人化治療，進而改善患者的治療效果。因此，人們明顯關注利用先進活體組織切片技術的見解進行標靶癌症治療。

整個癌症活體組織切片行業根據活體組織切片類型、產品和服務、癌症類型、最終用戶和地區進行分類。

組織活體組織切片領域預計在預測期內將以 8.3% 的複合年成長率成長，包括針吸活體組織切片、手術活體組織切片和其他組織類型。其市場主導地位源自於其作為癌症診斷黃金標準的地位，提供高度準確和可靠的結果。組織活體組織切片提供深入的組織學和分子見解，對於精確的腫瘤表徵和後續治療決策至關重要。它們的可靠性涵蓋了各種癌症，包括乳腺癌、肺癌和前列腺癌，微創技術和影像技術的進步提高了精確度和安全性，這增強了它們的可靠性。

乳癌領域的需求激增，預計到 2032 年將達到 87 億美元。 NCI 的數據表明，從2013 年到2018 年，乳癌發病率每年穩步上升0.5%，預計到2023 年將新增297,790 例乳癌病例。治療方面進步的迫切需要，從而刺激了需求用於活體組織切片。此外，先進活體組織切片技術的可靠研究和臨床證據擴大了該領域的需求，強調了其在解決全球乳癌負擔方面的重要性。

亞太地區癌症活體組織切片市場預計將迅速擴張，到 2032 年複合年成長率將達到 8.7%。這一趨勢推動了對先進活體組織切片技術的需求，這些技術有望實現精確診斷和有效治療。此外，在政府措施和醫療保健投資的支持下，該地區尖端活體組織切片技術的可近性增強是該市場成長的重要推動力。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 癌症盛行率上升
      • 癌症切片技術的技術進步
      • 對遺傳性腫瘤疾病和基因檢測的認知不斷提高
      • 擴大研發
    • 產業陷阱與挑戰
      • 切片設備成本高
      • 嚴格的監管要求
  • 成長潛力分析
  • 技術景觀
  • 未來市場趨勢
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按活體組織切片類型，2021 - 2032 年

  • 主要趨勢
  • 組織切片
    • 針吸切片
    • 手術切片
    • 其他組織切片類型
  • 液體活體組織切片
    • 循環腫瘤細胞 (CTC)
    • 循環腫瘤 DNA (ctDNA)
    • 其他液體活體組織切片類型
  • 影像引導活體組織切片
  • 其他活體組織切片類型

第 6 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

  • 主要趨勢
  • 產品
    • 切片針/槍
      • 細針穿刺切片檢查 (FNA)
      • 空心針切片檢查 (CNB)
      • 真空輔助切片裝置
    • 切片鉗
      • 普通活體組織切片鉗
      • 熱活體組織切片鉗
    • 試劑盒和試劑
    • 耗材
  • 服務

第 7 章：市場估計與預測：按癌症類型，2021 - 2032 年

  • 主要趨勢
  • 乳癌
  • 大腸直腸癌
  • 胃癌
  • 肺癌
  • 肝癌
  • 攝護腺癌
  • 卵巢癌
  • 其他癌症類型

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 癌症研究中心
  • 診斷中心
  • 研究與學術

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • ANGLE plc.
  • BD (Becton, Dickinson and Company)
  • Biodesix (Integrated Diagnostics)
  • Chronix Biomedical, Inc (Oncocyte Corporation )
  • Devicor Medical Products, Inc.
  • GRAIL, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • IZI Medical Products
  • Lucence Health Inc.
  • Myriad Genetics, Inc.
  • Oncimmune Holdings PLC
  • Personal Genome Diagnostics Inc.
  • QIAGEN N.V.
簡介目錄
Product Code: 10995

The Global Cancer Biopsy Market was valued at USD 21.5 billion in 2023 and is projected to expand at a CAGR of 8.4% from 2024 to 2032. This growth is fueled by the rising prevalence of cancer and advancements in diagnostic technologies, particularly biopsies.

Techniques like liquid biopsy and next-generation sequencing (NGS) are gaining traction for their precision and minimally invasive approach. These advancements are revolutionizing cancer diagnostics, offering methods that are both less invasive and more accurate for disease detection and monitoring. A 2019 report from the National Cancer Institute (NCI) highlighted that liquid biopsies could detect genetic mutations in over 70% of advanced cancer cases, aiming to bolster early detection, tailor treatment strategies, and enhance patient outcomes.

Heightened awareness of inherited oncology disorders and the significance of genetic testing is amplifying demand. These technologies facilitate early detection and personalized treatments, leading to better patient outcomes. Consequently, there's a pronounced focus on targeted cancer therapies, harnessing insights from advanced biopsy techniques.

The overall cancer biopsy industry is classified based on biopsy type, product and services, cancer type, end-user, and region.

The tissue biopsy segment, projected to grow at a CAGR of 8.3% during the forecast period, encompasses needle biopsies, surgical biopsies, and other tissue types. Its market dominance stems from its status as the gold standard in cancer diagnosis, delivering highly accurate and dependable results. Tissue biopsies provide in-depth histological and molecular insights, crucial for precise tumor characterization and subsequent treatment decisions. Their reliability spans various cancers, including breast, lung, and prostate, bolstered by advancements in minimally invasive techniques and imaging technologies that enhance both precision and safety.

The breast cancer segment is witnessing surging demand, predicted to hit USD 8.7 billion by 2032. The global uptick in breast cancer cases underscores the pivotal role of biopsies in its management. Data from the NCI indicates a steady 0.5% annual rise in breast cancer incidence from 2013 to 2018, culminating in an estimated 297,790 new cases in 2023. This escalating prevalence accentuates the pressing need for advancements in detection, diagnosis, and treatment, fueling the demand for biopsies. Furthermore, robust research and clinical evidence for advanced biopsy techniques amplify their demand in this segment, underscoring its significance in tackling the global breast cancer burden.

Asia Pacific cancer biopsy market is set for swift expansion, with a CAGR of 8.7% through 2032. The region's growing embrace of genetic testing underscores the vital need for timely and accurate cancer detection. This trend propels the demand for advanced biopsy techniques, which promise precise diagnoses and effective treatments. Additionally, bolstered by government initiatives and healthcare investments, the region's enhanced accessibility to cutting-edge biopsy technologies is a significant driver of this market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Technological advancements in cancer biopsy techniques
      • 3.2.1.3 Rising awareness in inherited oncology disorders and genetic testing
      • 3.2.1.4 Expansion of research and development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of biopsy devices
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Biopsy Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tissue biopsy
    • 5.2.1 Needle biopsy
    • 5.2.2 Surgical biopsy
    • 5.2.3 Other tissue biopsy types
  • 5.3 Liquid biopsy
    • 5.3.1 Circulating tumor cells (CTCs)
    • 5.3.2 Circulating tumor DNA (ctDNA)
    • 5.3.3 Other liquid biopsy types
  • 5.4 Image-guided biopsy
  • 5.5 Other biopsy types

Chapter 6 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Products
    • 6.2.1 Biopsy needles/ guns
      • 6.2.1.1 Fine needle aspiration (FNA)
      • 6.2.1.2 Core needle biopsy (CNB)
      • 6.2.1.3 Vacuum-assisted biopsy devices
    • 6.2.2 Biopsy forceps
      • 6.2.2.1 General biopsy forceps
      • 6.2.2.2 Hot biopsy forceps
    • 6.2.3 Kits and reagents
    • 6.2.4 Consumables
  • 6.3 Services

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Breast cancer
  • 7.3 Colorectal cancer
  • 7.4 Stomach cancer
  • 7.5 Lung cancer
  • 7.6 Liver cancer
  • 7.7 Prostate cancer
  • 7.8 Ovarian cancer
  • 7.9 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Cancer research centers
  • 8.4 Diagnostic centers
  • 8.5 Research and academics

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 ANGLE plc.
  • 10.2 BD (Becton, Dickinson and Company)
  • 10.3 Biodesix (Integrated Diagnostics)
  • 10.4 Chronix Biomedical, Inc (Oncocyte Corporation )
  • 10.5 Devicor Medical Products, Inc.
  • 10.6 GRAIL, Inc.
  • 10.7 Hologic, Inc.
  • 10.8 Illumina, Inc.
  • 10.9 IZI Medical Products
  • 10.10 Lucence Health Inc.
  • 10.11 Myriad Genetics, Inc.
  • 10.12 Oncimmune Holdings PLC
  • 10.13 Personal Genome Diagnostics Inc.
  • 10.14 QIAGEN N.V.